In this study, we investigated the effect of ULBP2, a ligand for NKG2D, on the efficacy of CD4+CD25+ T cell-targeted immunotherapies using a CT26 mouse colon cancer model engineered to ectopically express ULBP2. This evidence concerns the gene CD4 and colonic neoplasm.